Key facts
- It has raised $82.9M across 4 recorded rounds; the latest was Early Stage VC ($45.2M) in Mar 2024.
- Notable investors include Arboretum Ventures, Versant Ventures, Alcon, Falcon Vision (United States), Venture Investors Health Fund.
- ViaLase has filed 6 Form Ds with the SEC since 2019, most recently Sep 2024 ($45.2M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ViaLase
Funding rounds
4 roundsAbout ViaLase
Developer of a laser surgical system intended for the treatment of open-angle glaucoma in patients. The company's system focuses on the development of micron-resolution optical coherence tomography (OCT) image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to the Schlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment.
- Sector
- Healthcare
- HQ
- Aliso Viejo, CA, United States
- Founded
- 2019
- Employees
- 29
- Website
- vialase.com/
- Ownership
- Privately Held (backing)
ViaLase doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ViaLase shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ViaLase in its N-PORT filings yet. We sweep new filings monthly.